Literature DB >> 18948587

Why is CLL refractory to bortezomib?

Ranmohan Gitendra Wickremasinghe1.   

Abstract

Entities:  

Year:  2008        PMID： 18948587     DOI： 10.1182/blood-2008-07-171231

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors:  Farrukh T Awan; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami J Maddocks; Ellen J Sass; Margaret S Lucas; Weihong Chase; Sharon Waymer; Yonghua Ling; Yao Jiang; Mitch A Phelps; John C Byrd; David M Lucas; Jennifer A Woyach
Journal:  Leuk Lymphoma       Date:  2015-03-11

Review 2.  O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.

Authors:  David E Spaner
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 3.  Why bortezomib cannot go with 'green'?

Authors:  Li Jia; Feng-Ting Liu
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.